Qualigen Therapeutics, Inc. (QLGN) (the “Company”) announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors of the Company (the Board") of his intention to resign as chief executive officer and Chairman of the Board of the Company, effective immediately. On the same date, Mr. Christopher Lotz, Chief Financial Office also tendered his resignation from the company, effective immediately. Both resignations were attributed to disagreements with the Company regarding its future direction and strategic initiatives.
On September 25, 2024, the board of directors appointed Campbell Becher as President of the Company, effective immediately.
On September 26, 2024, the board of directors appointed Kevin Richardson as Interim Chief Executive Officer and Chief Financial Officer as well as a member of the board of directors. Mr. Richardson has extensive experience in leading strategic and turnaround efforts in various small cap companies. “I am excited to be given the opportunity to lead Qualigen as it embarks on new strategic initiatives that will enhance shareholder value”. Mr. Richardson most recently served as CEO of Sanuwave Health Inc., a medical device startup that Mr. Richardson took from a fledgling operation to $20mm in revenue.
New President Campbell Becher shares Mr. Richardson’s enthusiasm for the future. “We are entering an exciting time at Qualigen with many potential opportunities ahead. We would like to thank Michael and Chris for their years of leadership and guidance at Qualigen.”